Gland Pharma · NSE: GLAND · BSE: 543245
Q3 FY25 results · Oct–Dec 2024
Gland Pharma reported revenue from operations of ₹1,384.05 crore (down 10.4% from Q3 FY24) and net profit of ₹204.69 crore (up 6.7% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,384.05 | 1,545.15 | −10.4% | 1,405.83 | −1.5% |
| Other income | 58.49 | 37.39 | +56.4% | 59.66 | −2.0% |
| Total income | 1,442.55 | 1,582.55 | −8.8% | 1,465.49 | −1.6% |
| Profit before tax | 299.30 | 283.16 | +5.7% | 256.78 | +16.6% |
| Net profit for the period | 204.69 | 191.86 | +6.7% | 163.53 | +25.2% |
| EPS, basic (₹) | 12.42 | 11.65 | +6.6% | 9.93 | +25.1% |
| Net margin (%) | 14.8 | 12.4 | 11.6 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,010.78 | 1,097.86 | −7.9% | 1,062.99 | −4.9% |
| Other income | 65.06 | 43.39 | +50.0% | 57.80 | +12.6% |
| Total income | 1,075.85 | 1,141.25 | −5.7% | 1,120.79 | −4.0% |
| Profit before tax | 394.13 | 371.75 | +6.0% | 379.82 | +3.8% |
| Net profit for the period | 295.12 | 276.81 | +6.6% | 281.71 | +4.8% |
| EPS, basic (₹) | 17.91 | 16.81 | +6.5% | 17.10 | +4.7% |
| Net margin (%) | 29.2 | 25.2 | 26.5 |
Consolidated
- Filed with BSE
- 03 Feb 2025, 21:43 IST
- Board meeting
- 03 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Feb 2025, 21:43 IST
- Board meeting
- 03 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE